throbber
AN”l'AT|ON
`
`Roxane Labs., Inc.
`Exhibit 1031
`Page 001
`
`

`
`This material may be protected by Copyright law (Tftle.17 U.S. Gode)
`
`Rapamyc. ins: An... tifungal1 Antitumor1
`Antiproliferative1 and
`Immunosuppressive Macrolides
`Randall Ellis Morris
`
`Hlhat in-loow ira drop. H'liritwtrion_-} bwwiI 1111 «tim.
`bMcNrultm
`
`P rogress in rapamycin (RPNI) research has been
`
`rapid and is poised to accelerate even more
`dram<t;tically. An Investigational Nf!\V Drug applica(cid:173)
`tion (IND) for phase I tfials of RPNI as a treatn1ent
`for prospective graft recipients was approved less
`than 2 years after the first published reports1.1 and
`Pl!hlic disclosure' of the al>ility of RPNI to. prO!ong
`graft sUniival in experimental animals. RP~I is _a
`macro~de fermentation prcxluct th.it h<¥> antifungal
`and anlitumor activity. However, its effects' on the
`immune system have generated the most interest
`because RPM is structurally similar to another new
`lrnmunosuppressive macrolide, l<'K506. RP1'1 is par(cid:173)
`ticularly intriguing because it inhibits the activation
`of hnmune cells by unique, relatjvely selective. and
`extremely potent and highly effective mechanisnu.
`For example, o~c half microgram of "R.P1'1 ad minis~
`tered daily to mouse recipients of cotnpletely 'n1is-
`01atched heart aUografts prolongs graft survival.
`When these mice arc t_reated for only 2 weeks ·with
`higher doses of RP1'1, or when a siqglc dose of RP~! is
`administered to rat heart aJlograft recipients, strain(cid:173)
`spe<;ific unresponsiveness is induced, .and grafts sur(cid:173)
`vive in'r;lefinitelyin both spedes.
`'The r·csearch on EPN! is rcprcscntath•c of a
`signiflca_nt shift in e1nphasis in transplantationfrom
`the 1nacrocostnic world in which innovative surgical
`techniques predominated fron1 the 1950s through
`the 1970s to our current focus on the microcosm of
`cellular and 1nolecular immunopharmacologr. A re\'(cid:173)
`olution in the discovery, development, and clinical
`use of new strategics to control the immune response
`is dearly upon us: it took more than 35 years to
`
`P-10;,1 tM i.AhxaltA.J fr Trarupla11/a/ioo IW11U1~lf, Dtpirtrr.n_:J ef
`birrliolharndr Su,,;ay_. StntJ!Wl lllntt-~i!r Srf.col ef.\/trfid>ir, St111!_/01rJ,
`CA
`.4'Jdrrss rrfxinl rtqunlf /ti Ran&i/l E/Us .lfooir, MD, Lnbxo.twy j.v-
`1ia111µanlatiw. lm1mm@g, lkparlwnl rd lim/Wlhmxfr Sm~ny, Sla11-
`farf U11frmi!J Sdiwl oj.\foiidu, S1aefxd, CA 94105-5217.
`Cof:Jrr(F/11o1992hy IVJJ. SaumkrrCw1/xHIJ'
`0955-./ 70.YJ 921{)(Jl)/.OOOJS5.f)O/0
`
`arcrue the four imperfect mainsta}'S of immunosup(cid:173)
`prcssion for tra.nsplan~ation-~teTQids1 azathioprine,
`anti-T-cetl antibodies, and Cydosporin A (CsA). In
`1992, six new xcnobiotic immunosupprcssantswill be
`in clinical trials (Fig I).
`This new Crain in1munosupptcssion can be traced
`to the convergence of several lines of rt'seiirch: (I)
`the discovery and suct&ful ~linical use of CsAi (2)
`an increased understanding of the fundamental biol(cid:173)
`ogy of i'mmune c'cUs that enables th.e actions of
`different in1munosuppressants to be better J,Jnder(cid:173)
`stood and thus lay the foundation foi mofc rational
`means to discover, develop, and use improved drugs;
`and (3) orgiti-i1ied preclinical- fC!i_earcl1 proSrams
`designed to id en tif y potentially yalu_abie irilmunosup(cid:173)
`pressants and to gcfic~te the knowledge needed for
`these agents to be used intelligently in t_he clinic.
`Figure 2 shows the research pr~S"ram used for several
`years in the Labor8.tory forTranspl311tadonI~munol­
`ogy at Stan[ord Un!~·~rs:lty that enab_fed us tO identify
`RPNI:s- 11 and the morpholinomethyI este"r"of m)'cophc(cid:173)
`nolic acid (1-£PA) 1~·16 . as immunosupprcssants for
`graft rejection. The mi;chanisms of action andimmu(cid:173)
`nopham1acology of th'cse two cmnpounds, as well as
`19 deoxyspcrgualin (DSG).~ 1 a,nd brequinar
`FK5Q6,11
`•
`sodium (BQR)n _have _<Uso been studied and com(cid:173)
`pared with one another in ~u1· Jakratory.
`Our spectrum of experimental ~terns begins
`with in vivo mouse models that are so rapid, quantita(cid:173)
`tive, and inexpensive that we have been able to
`evaluate hundreds of molecules for suppression of
`alloimmunity. 'fhc vast majority of these drug candi(cid:173)
`dates fail during testing in rodents because they lack
`efficacy or safety, and they are diScarded quitj\ly so
`that our resoun:cs can be concentrated on com(cid:173)
`pounds with the greatest potential. Co1npounds that
`sho\V promise are evaluated further in rodent models
`to identify those with the following ideal Characteris(cid:173)
`tics: (I) uniqtie _mode of action; (2) high efficacy for
`the prevention Or treatment df acute, acrclerated, or
`chronic rejection; and (3) low toxicity. This DarA>in(cid:173)
`ian selection process acromplishes h\'O tasks: first, it
`insures that only the agents \vi.th the greatest po ten~
`
`Trmupla11tatio11 Rnini;s, Vol 6,A'o I (Janum;~, 1992: pp39-87
`
`39
`
`Roxane Labs., Inc.
`Exhibit 1031
`Page 002
`
`

`
`40
`
`R11.ndall Ellis .\fonis
`
`M!ZORIBINE
`DEOXYSPERGUALIN
`FK506
`MYCOPHENOLJC ACID
`AAPAMYCJN
`BREQUINAA SODIUM
`
`CYCLOSPOAINE
`OKT3 l.tAb & OTHER MAbs
`
`CORTISONE
`AZATHIOPRINE
`ANT!-T CELL Abs
`
`1950
`
`1970
`
`1980
`
`1eao
`Figure 1. History of the use ofdn1gs used lo control_ graft rejection. AH of the foJJowingxenobiodcs recentlydhcm·ered to
`suppress gtaft rejection in prediniral models. have ndvnnced to clinkal trials: the nntimetaOOlites. such as mi7.oribinr.(cid:173)
`(i\JZR), i\IPA in its prodrug form ofRS-6H43, and BQlt; the cydosfK>rine-likr chug FK.506, and drugs that define two new
`c!assesnfimmuno:iuppn•.<iS.1nts, fi')G ancl RP.\{.
`
`1990
`
`2000
`
`tial are advanced to the expensive nonhutnan pri(cid:173)
`mate transplant model; and second, it prepares. us to
`be able to use these compounds. intelligently in
`nonhuman pd1nates. TI1e nonhuman primate n1odcl
`is important because it is highly prcdicti,·e of the
`safety and efficar..)'of a test drug in humans. The suni
`of all knowledge produced from well-planned preclin-
`
`kal studies is the essential foundation fro111 which
`succcssCul clinira.I trials arc designed and executed.
`New drugclcvclopment is a highlycon1plcx, 1nultidis(cid:173)
`ciplinal)' task, and our contribution to the develop(cid:173)
`ment and clinical use of new ilnnnmosuppressants
`depends on \'cry close collaboration with scicn.tists
`and clinicians in the ph<trmm:eutical industt)'.
`,
`
`FUNDAMENTAL ~
`IMMUNOLOGY /~
`
`/ • ""'
`. 4~~-~-~-
`n~ .....
`@ &
`
`' - - - - - - IN VIVO------'
`
`'-------DISCOVERY------~
`
`'------ DEVELOPMENT---~
`
`TRANSPLANTATION
`
`AUTOIMMUNE
`DISEASES
`L CLINICAL TRIALS _J
`Figure 2. &::hrmatic teprr~entation of the program used ;lC the Lahornto1yurTransp!anlacion Inununnlogy at .S1anford
`Uni\'ersily to idrntffycompounds \dth immunusuppressive activities fur 1111.mplantation J.lld to dew·!np these compounds
`for dinil."J.I ust: for the prcVi!ntion and trratmcnt of rejecti011. Fund;.uncnta! knmdedgr of Lhc immune system couplrd with
`an nppre_ciation of thr d1ararteristics of the clnig c-.mdidatr is usrd to dt·Sig"ll't>XJ>criments lo profile the activity nr the
`~ompoundanddt:fine- its rnrdmnismsofaction. Hcterntopic transplantation ofnronatnl muu.~e heart <1llug-rnrts into the enr
`pinrr.1e or moust' recipients and alhJantigcnk and mitugt:nic stimuli ur pop!iteal !)1nph nrnle hrperplasia an: used as rapid
`and quanlitalil-e bioas'ltly:s beforr proceeding lo the more laborious technique~ uf primarily \"U.Scula.rize<l heteralopic
`(abdominal) and secomlarily\nscularize<l h!!tt:rotopic (subrcnal capsule) heart al!ngrnft nnd xcnograft transplnntion in the
`ral. As.'ir,'Qmrnt nr the dlicnty and tht' safety oCLhe mmpnurul in cynomulgus monkey n•ripicnts ur hete.nitopir r1!1ograJts
`pn~crdt's phase I c!inil·.iJ trials in lransplmll pa.dents and µati1·11Lo; with autoimmune disr:i~es.
`
`Roxane Labs., Inc.
`Exhibit 1031
`Page 003
`
`

`
`41
`
`~t fj\
`
`~ + .... ~ ~1FULLV
`
`ca2•.DEPEHDENT ca2t.1NDEPENOENT
`
`UGNlOS
`
`LIGAND
`
`TCR-COO CDOOOS
`
`0028
`
`•
`•
`f
`f C<>2 LFM
`IA\
`.
`L
`ti~K..·~ ~~!Vl.._
`~ ,.. CITO~>"S
`>L·•
`
`-
`
`-
`
`-
`
`-
`
`OlffER-
`
`MZR '@ @ ='°
`
`FK50B
`
`RPM
`{B CELLJ
`
`DSD
`(Bml}
`
`~;:
`{B CEll}
`0 0-01--------------s ... az+ld
`Fi~~e 3. ~hernatic representation ol'lhe possible sites of action of the follm1ing irimnmosupprcssants 1m activated T
`re)!s: CsA and FK.506 PIT\'l'nl the trm_l~niptiun ofeadr t1huse c:ytnkine genes; RP11 inhibits the signal transduction ofIL.2
`bound to its receptor and mar hm·e other antiproliforali\'e effects unrelated to lymphokinesigimls; ~lZR, ~WA, and BQR
`all inhibit purine (:\IZR, ~IPA) or p)limldhie (BQR) nucleotide S}1llhesis; DSG seerris to inhibit late stages of T·cell
`maturation. RPAf, :\lZR, ~fPA, BQR, :mO DS,G also tn:t _oi1 ncti\'atcd B cells at the sites shm\n,
`
`Even fuore importan~ than the relatively large
`number ofncw'imrpunosuppressants th<lt have been
`<lisCovered _js their variety. Each pf these. new molc(cid:173)
`c:ules su.ppresses ·the in1n1une system by blocking
`distin~tlydiffcrent bjoch~mical reactions that initiate
`the <\_ctivation ofjmmune cells that cause the ma,ny
`f<?rf!lS .of graft rejection (Fig 3) .. Bfieqy. 9sJ\ an.cl
`F_K5Q6 Uct soon after CaH-dePendent ·T-cell activa(cid:173)
`tion to prevent the syntheSis of_cytokincS impcirtaJ11
`for the ~rpctU<ltion a~d an1plification of the i111-
`mun~ re!ipotj:se."-13 RP~f acts 1ater t9 block multiple
`effects-. of c}1okincs rin in11nunc cells including the
`inhibi.tion ofinterleukin-2-(IL-2-)triggered T-cell pro(cid:173)
`lif erati9n,')-)..1t but its antiproliferative effects are not
`restricted solely to T and B tells. RPM·alsd selectively
`inhibits.the proliferation or growth factor-dependent
`and grmvth fhctor-indepcndent -nonimn1une cells.
`i\·fizoribine (1·1ZR)/! ~IPA,1 1 and BQR:u arc antin1e(cid:173)
`tabolites that inhibit DNA synthesis pli1na:ril)· in
`l~phc>cytcs. These n·ew antimetabolites are more
`selective than azathioprine because these con1-
`pounds block the activity of CO:l.)TI1Cs restricted only
`to the de nova purine or pyrimidine biosynth~tic
`pathways. LymphOC)1csare inore dependent on these
`pathv,iays for nucleotide synthesis than other cells.
`Recent re\'iews1
`>-"5ll discuss these and other in1mu(cid:173)
`nosuppressants. RP1'1 has recently been the subjec;t
`nf four brie-f re\'icws,'.:n-11 a long revicw,-1-~ and 'has
`been included in reviews thn.t have pri1narily focused
`on FK506. un.This rc\<ie.\v pro\~des a co1nplcte profile
`of RP?i.-1 from work published through the end of
`August 1991. Despite the progress 111ade in under(cid:173)
`standing RP~-1 since the first publication on this
`compound in 1975,l'i the pescription of its ability to
`suppress graft rejrction has stimulated renrwed
`
`interest by a \\idc variety of investigators whose work
`has not yet been published. As a result, research on
`macrolide immunosupprcssant.s has become fluid
`and extremely fast-paced. Bc~ause unpublished data
`generally are not available-for evaltiation, I have i16t
`referred to unpublished work or personal cdfhtnuni(cid:173)
`cations. Hm\·evCr, I have reiied on ·many studies of
`RPi\f from the Laboratoryo(Tran.spl_antatiori Imrnu·
`nol_ogy at.Stanford Uniyersity th.\\t have yet to _be
`publiShed in full. In niost of these. qi.scs,, I h~ve
`supplied the data f~mn \vhich ~onclusioh~ in the 't~xt
`are drawn.
`Because this review· is being written relatively
`early in the researdi lire of RP.~1, and because the
`majority Of the ,\urk on this corilplex moleCule has
`yet to be published, the 1nateri51l ~bsequently pre(cid:173)
`sented should be regarded, more a.s a )1re\iew rather
`than as a review. A_t the very lea~t. this a'rtide \viii
`pro\~dc a logical framework th.1.t o~hcx investigators
`can use to organize and to evaluate 'new information
`on RPi\·I as it is published. For n1any investigators
`"1th highly specialized interests, only selected sec·
`lions \\-ill be of use. For 9the'ts, it is essential to
`understand all that is knowfl about a new and unique
`1nolcculc s_uch as RPi\-I. Without an understanding of
`RFl\.[ that is both decp11nd broad, it 'viii be difficult to
`1neet the challenging tasks of using-RP!\{ as ·a tool to
`learn more about the in1n1unc S)'Sten1, ma.,.imizing
`its thcrapc.utic potential, and discoycring new and
`in1pro\•cc! 1ncmbcrs of this class of i1nmunosuppres(cid:173)
`sant. Jfwe strive to understand thoroughly the little
`that is now known about RP1\'f, \\'C \\1ll 1nake more
`efficient and rapid progress toward our goal of
`understanding all ur the imr.or1ant biological effects
`of this 1nolecllle.
`.
`
`Roxane Labs., Inc.
`Exhibit 1031
`Page 004
`
`

`
`42
`
`Randall EHis .lloni1
`
`~'' ~~~~~~~~"'cruc''~~~~~~~~~~
`t!l<· UEC~SWllHS:<tt
`tilS
`OFIL!>Jt,Jl.,'{;C8-l
`..CTIVATIOl"lSHCT"'I
`"1\IITTlOA\il!N'il.'tl
`
`111;
`
`ma
`
`1:;&J
`
`1~1·
`t;.l!)
`
`1~..3 FOA~.<.LAMJ
`COll>IO'>ICU'ICl!..IJSe
`"TR.>..'>5f'l.>XTATION't;
`
`sa>ITl<I
`F£P.llUilAID'I
`Pl\00\.<:lSFOi\
`NroTOl1SOf
`ll<E;l.t.'J!>SEr.H~O
`LYW'HCY.;YTEl'.V.CTIO'I
`
`I~-
`1;!!
`
`1™
`
`11.~~E
`AllTMT1' 9JO'MH'i
`ViTJiOl .... OL'JYNO
`
`\11<;1.le.IW'Mrl"t.'lllq;
`Stf<LICfU:::~OEf?',"ED
`
`).'ffi.--1.N:J,.!.\.,OCll'•iTI',
`lOO TOl:r.m SHO>'i:i
`!l.fllt.Q5\,P,!'Z$.S>:'lN
`Ofll.JTO)."Jl.l'..e:
`0$US~~l'.S
`
`l,l'>ClUB!N:.<OIJDE
`STR>.mt.IR£C~"'EO
`
`N<E5TIG.-\Tcti
`OfAAPAlfftN
`~).'INlll,t;Q.
`st:F9il£SS-lo'ITFOil
`Ti'A'<Sl"IA~l.ATJON
`
`j
`
`P.l.l'IJ~l"UI
`~TO PRa,miG
`MiOOPMTSl.'<&11/.J.
`
`Figure 4. Evol.utionaiy path ofRP.i\'f as an immunosup(cid:173)
`pres5anl for transplantation.
`
`In addition to reviewing the inforn1ation on RPli.-1,
`this article warns of the danger of inductive reason(cid:173)
`ing in which, in an adolescent field like immunolot,')',
`arguing from highly specific cases to general laws
`
`often promotes the illusion of knowledge rather than
`its true acquisition. Howc\'cr, br interrelating infor-
`1nation conccrningthe structure, the 1uu!ccu/ar n1ech(cid:173)
`anisrns, and the actions ofRP!vl on drfined cdl t)ves
`in vitro, its effects in vivo, as well as its disposition in
`the body and its toxicity, new and in1portant insights
`into the actions of RPi\·I can be gained. In general,
`the conceptual tools used in this review to analyze the
`data from experin1cnts on RPll..Ican be applied to the
`study of many other itnmunosuppressants, <"specially
`other xcnobiotics.
`Before dissecting and exntnining every aspect of
`RPi\,[ in detail, it is worth reviewing the events that
`led to the attention RPi\·f is now -receiving. Figure +
`shows the relationship of the.evolution of RPN1 as an
`in1n1unosuppressant to the develop1nent of CsA and
`FK.506 as im1nunosuppressants. Table I proddcs a
`n1ore detailed outline of the sequence of the inain
`events that have defined progress in RP1•1rescarch in
`its firsl 15 years. 1421'~i&i.! The ancestors of RPri.'1 are
`CsA and FK.506. As shown in Fig 4, CsA stin1ulatcd
`the organi7.ation of a rational screening progratu
`designed to discover other fcnncntation products
`\\1th mechanisn1s ofin1munosuppressive action iden(cid:173)
`tical to CsA. The discovcryofFK506was the product
`of this program,i1 and "'hen the structure ofFK506
`was defined, its similarity to the structure of RP~.f
`was immediately recognizcd."1 Years before, the
`structure of RPi\I had been cletern1i11cd as a consc-
`
`Table 1. HistoryofRP~f Drug Desdopmenl: Thr First ]j Yt>ar.o;
`
`TsolntiOJJ from Ea~ter Island (Ra1xi Nui) soil
`.sample and characterization ofantimicro(cid:173)
`bin! nctidty
`Jn \'h'O uSe:
`Tuxicil\'
`Pharm;cokinetics
`Bioa\·.iik1bilitv
`Antifungal a~tivity
`Immunosuppression or autoimmune dis·
`ease
`Elucidntiun of structure
`Antilumol' activltv deseri!xd
`Immunnsuppression of a!logrnft rejection
`RP.~1 alone
`
`RP}.l in combination with Csr\
`Diffrn:nti<ttiu11 uf effects ufRP}.f and FKSOG
`on immune rdl~ in vitro
`
`Diffrren\intion of effects of RP~f and FlGOfi
`on immune S}Stem in vhu
`Demon~tratiun urliimliug: urRP}.I tu FK501i
`binding prntein
`
`1975
`
`1978
`
`1977
`
`1980
`191ll
`
`1989
`
`] 99{)
`1989
`1990
`
`19'XJ
`
`1989
`
`Vt!zina, Km-lel$ki, and Sehgal.ii;
`Sehg•li, Haker, and Vezina 1
`;
`
`Baker, Sidorm~icr, Sehgal, et al''.
`
`l\fartel, Klicius, nntl Ga!etH
`
`Findlay and Rad ks'"
`Duuros nm! Suffness1'
`
`i\Iorris and i\-feiser 1
`C:alne, Collier, Lim, et ilf
`i\[t"i~f'r, \Vang, and }..{orrisJ
`'ford, l\Jatkovich, Collier, el a!'1
`:\Ietralfe nnd Richards.!!
`Dumont, Staruch, Koprak, rt al:r'
`i\Jonis, \Vu, ant! Shorthnu~e 1
`
`;
`
`Harding, Cn!nt, Uehling, et al"'
`
`Roxane Labs., Inc.
`Exhibit 1031
`Page 005
`
`

`
`Rnpan~Jri11r
`
`43
`
`quence of the identification of RPM as an antifungal
`antibiotic (Table 1). Shortly after the antibiotic
`activities of RPM \\'ere described, it was found to
`have imn1unosupprcssive activity.1'his was oid}' a few
`}'cars after. the immunosuppressive activity of CsA
`was discovered, hut ironically, RPh-1 was not de..•cl(cid:173)
`opcd as an immunosuppressant at that time. In a
`review;;; of immunosupprcssivc agent.s published in
`1988, Devlin· and Hargrave encouraged "ii detailed
`comparison of the biologica1 profile of these ma:c(cid:173)
`rolides [FK.506 and RPM]." 1bcse inmtigators sug(cid:173)
`gestion was based on the structural sin1ilarityofboth
`compounds and their knov.n immunosuppres.si\•c
`activity.
`Sehgal was aware that investigators at the L'lbora(cid:173)
`tory for Transplantation Immunology at Stanford
`University had developed a_quantal bioassay for the
`evaluat_ion of immunosuppressant potency and ef(cid:173)
`ficacy, had validated the assay 'vith Cst\/1 and.had
`µsed it .to study FJ{506." In 1988, he offered to
`provide us with.enough RPl\{ to.enable us to deter(cid:173)
`mine whether .its activity differed fro1n 1'1\.506 in
`mouse as well .. as rat heart transplant recipients. As
`subscquendy discussed,- the·activity·of RP~·f is ex(cid:173)
`tremely dependent on the vehicle in whici1 it is
`sus~nded and the route b)•which it is ad1ninistered,
`Had ourfin;:t e~perimcnt u.sedsuboptimal conditions
`: for the ~dministration ofRPNI, we would have found
`no difference in potency 'or efficacy between· RPA-1
`and FK506 and. might not have pursued our shidy of
`RP~·I. IO retrospect, the mode of admini.'>tration used
`at.the outset was optirrial and, under thosC condi(cid:173)
`tio1fs, RPM· was clearly more potent and effective
`than Fl\.506. This clear difference in p~1arn1acological
`effect betv;cen these t\vo structuni,lly related mac(cid:173)
`rolides prompted our continued investigations Qf the
`activity of.RPM At the same time as these stµdies
`were being conducted, investigators at the Uqiversity
`ofCambricfge, England, were testing the innnunosup(cid:173)
`_pressive activity of RP~'1 in rodents, dogs, and pigs. 1
`Siinl!ltaneous studies11
`·"l'J perfonncd at Cambridge
`and by various groups of investigators at }..ferck
`Sharp and Dah111e Research ~boratories, United
`States showed that RPM and FK506 affect imn1une
`cells quite diffcrcn.tly in vitro, .
`
`oo •.
`
`f!APAlNCIH - Rt" OCH, flp OH
`Iii" 11, Ri: Ott
`OElilETHOXYRAPA\iYC,111
`
`fk»I
`
`IU{-[JWETH"l'l.Gt.YC-JIATE
`l.l:TI~ SVLfON1C ADO S>.LT
`'
`I
`R,... 1 .... oJ......."-.. o-1,ro;-t
`
`~N·O£TlM.JJl..tlO;POO!'IOOATE ll'l"MOCHl..OFIOEW..T
`'
`!\.. J .... oJ....,...-...,.;...... oo
`'-
`
`~~,SUJl'RATE ll'l~CRUESALT
`
`,,.,_~o.~
`
`Figure5. Chemiatl structures OfRP1·f, 29-demethoxyra-
`p.arpydn, FK5CH;; a.nd the prudrugs ofRP~f.

`
`tj~s. jn the; m.iddJe 1970s.ffi.H The aerial m}i:elium of
`this b~ctcriun1 is. monopodally branchcQ (Fig 6),
`contains sporophores terminated py. short,, coiled
`spore chains, and absorbs \\'ater. It was ultimately
`identified ns belonging tO the! species Strrplon!)'<ts
`hygTlJS(opicus, designated by Arcrst Research as strain
`AY B-W4, and deposited in both thir ARS cqlturc
`collection of the United States Department of Agri(cid:173)
`culture (assigned n1;1mPcr NRRL 5191) and the
`American Type Culture Collection (ATC029253).A
`structurall}' related compound,y; 29-demctho.'\.-yra(cid:173)
`pam)t:in (AY~24,66R [Fig 5]) is coproduced \\1th
`RP1t Another culture isolated from the sa~e soil
`sample and designated AY B·I206 produces higher
`levels of RP.NI than AY B-994 and little or no
`29-dcmethoxyrapamycin.~1
`
`Fermentation, Purification, and
`In Vitro Aritiniicrobial Activity
`ofRPMs
`
`Origin and Characterization of the
`BacteriumProducing RPMs
`RP~l (AY-22,989 [Fig 5]) is made by a filamentous
`bactcriun1 frotn the strcpton1}i::etc group that 'vas
`isolated fron1 an Easter Island soil san1ple by Vezina
`et al and Sehgal ct al at Ayerst Research Laborato-
`
`Fermentatiori Of RPM
`Soun after the availability of a pure strain of S
`h;irosropicu.1, fr·rmcntation conditions (type of media,
`media pH, and tc1nperature) were varied to define
`its cultural charactCrislics.-lli.~ Although this microbe
`grows and sporulates in a wide range of culture
`
`Roxane Labs., Inc.
`Exhibit 1031
`Page 006
`
`

`
`44
`
`Randall EJliJ illorri1
`
`Figure 6. (A) Photomicro(cid:173)
`graph or the lilamentnus bac.
`te1ium, S hygrosropi(us. that
`produces RP;\f (magnification
`X-!53). (B) Electron micro·
`graphofSqygrrutopkw(magn.ifi·
`cation X2,500). (Reprinted
`with permission."')
`
`produce about 500 gm of oily residue from a J6Q.Jiter
`fennentation run. After extracting the residue with
`methanol, the extracts are evaporated to yield approx(cid:173)
`i1nately 50 gm of residue that is thenclissoked in 15%
`acetone in hexane and mixed \\1th silica gel, 'Ille
`dissolved RP!vf is adsorbed to the silica gel and
`remains bound to the gel after the mixture has been
`filtered and washed onto a column from which RP1,1
`is eluted with an acetone:hexane mixture. After
`e\'aporating the column eluate to dryness, the resi(cid:173)
`due is dissolved in ether from which pure crystals of
`RPI\i are obtained. In this initial purification process,
`recoveries of RPM are on the order of 40%; 10 L of
`broth produce 300 mg pure RPM. A more recent
`.
`method of purification has been reported.';;
`Except for minor n1odifications, the methods
`described for the isolation of 29-dcmcthm,·yrapan1y(cid:173)
`dn are the same as those used for RPNl ;(;
`
`In Vitro Antimicrobial Activity of RPJ\fs and
`J\feehanisms of Their Antimicrobial Actions
`The antimicrobial screening program at Ayerst Re(cid:173)
`search Laboratories identified RPI\{ for its antifungal
`acti\1ty. RP1·l inhibits the> gro\vth of yeasts and
`filamentous fungi including the dermatophytcsJ1icm(cid:173)
`JjJomm gypuum and Trid1oph_}'lo11 granuloswn. «'H The
`1ninih1um inhibitoIJ' concentrations (~1IC) of RP~i
`against ten strains of C albica11J were in the range of
`less than 0.02 to 0.2 µg/n1I, representing greater
`potency than that of amphotericin B, nystatln, or
`candicidin in this assay. RP~{ has no antibacterial
`activity. The spectrum of antimicrobial activity of
`29-demethoxyrapatnycin is similar lo RPNI, but its
`potency is only about 25% that of RP1[ although
`nearly as potent as a1nphotericin B.:ri
`One study ha'l investigated the n1echanis1ns br
`which RP~f mediates its antifungal r:ffcct'>,'"" and the
`results of this study are sum1narizecl in Tab!c 2.
`Approxin1atd}' 90 1ninutcs after adding RPl\I to C
`albicaiu cultures, growth is inhibited and subsc-
`
`conditions, more narrowly defined conditions are
`nccessaty for the optimun1 production ofRP!-.f. RP1'1
`has been produced by aerobic subn1erged fennenta(cid:173)
`tion similar to that used for tnost antibiotics. Inocu(cid:173)
`Ju111 is prcpa_red in two stages in a medium contain(cid:173)
`ing soybean 1neal) glucose, (l'U-I1)1'50l> and CaCO,
`and used at 2%, For the fermentation in stirred
`vessels, the starting 1neditnn was S0}1Jenn n1eal,
`glucose, (NHf)i)01, and KH1PO+· Glucose is fed
`continuous}}' after the 2nd day and the pH was
`controlled at 6.0 _\vith NH+Oll i\fa.,..irnum titers of
`RP1'[ arc _reached in 96 hours. Paper disc-agar diffu(cid:173)
`sion assays \vi.th Candida alhicmtr are used to deter-
`111inc the antibiotic titer.
`The formcntation n1etbods required to produce
`29-deniethoxyrapamydn are the same as ihose de(cid:173)
`scribed for RP~f_:.r;
`
`Purification of RP Ms
`
`The purification schetne (Fig 7} adopted for the
`production of RPM was developed shortly after the
`identification of the anti fungal activity ofRPlv! and is
`subsequently sun1n1arizcd.n After fermentation, the
`pH of the beer is adjusted to 'l,O. The 1nyccliun1,
`extracted with trichloroethane, is filtered offancl the
`extract is d1ied v.rith anhydrous sodiu111 sulfate to
`
`FERMENT STREPTOMYCES HYGROSCOPICUS
`
`EXTRACT MYCEUUM WITH ORGANIC SOL VEITTS
`
`APPLY CONCENTRATED EXTRACT TO SILICA OEL COLUMN
`
`I
`I
`I
`I
`
`ELUTE Wlnl. ACETONE
`
`RAPAMYClNS
`
`Figure 7. Ferm~ntatiun and isolation ofRP~-is.
`
`Roxane Labs., Inc.
`Exhibit 1031
`Page 007
`
`

`
`Tab~e 2. :iafechauisms of Antifungal Actions orRP~I.
`
`1'..Jftct ofRPJl
`Trta/111<nl
`
`Not inhibited
`Not i11cT\'asetl
`
`Not inhibited
`
`Not inhibited
`
`Not inhibited
`
`Inhibited
`
`Inliibited
`
`Inh(bited
`
`· Inhibited more for
`Ri.~A than QXA
`
`Increased
`
`Sorbose retention byC alhkmu.
`lm:reased hrmnl~1iis of rat t'l'd
`blood cells, effitiX ofK+,Pi,
`UV·absorbing material fmm
`Cafhicam.
`C albimns anerobic glyrol~1iis,
`:ierqbic respinttion.
`Pmlein synthesis by cell-free
`preparations: nfC alhicmis, E
`roii, rat lin:r, nncf mitochon~
`drial pn•i»irations ofCalhicmu.
`A1ilino add metabolism by glu(cid:173)
`tamic-oxaloacetic transami(cid:173)
`nase, g!ut;imic-P}TU\'ilte
`transaminase in C nlbit:a11s.
`Glurosamine and N-acet}1-glu(cid:173)
`rosamine incutporatiun into
`whole C albirmu.
`Oxidative deal'oination of glu(cid:173)
`li!-mkµnd nspartic ad~s in C

`olhiauu.
`In<:orpor.ltion Ofglucost: inlo
`tria1~nan in C alhicah1.
`Incorporatioh ofNaacetate and
`methionine into total lipid of
`c albi<OJJI.
`Iilrorpun1lion of adenine and
`phosphate into RJ"{A and DNA
`ore alhicans.
`Degtacla:tion of"'Zp_labelled intra(cid:173)
`!Ccl!ular macromolecules and
`leakage through C a!hirnn.r
`membrane.
`
`qucntlyycastcells lose viabilitrand begin to lrsc. The
`candiddal actions ofRPi'rl differ fro1n polycnc antibi(cid:173)
`otics that increase yea.'lit cell penucability by binding
`tosterols in the cytoplas1nicmc:mbrane, thus causing
`leakage of cellular con1pot!cnts. Not only do stcrols
`not reverse the actions of RP~'1, but RP~-I docs not
`increase the leakage of sorbose or the efflux of
`potassium, phosphate, or UV-absorbing 1naterials
`front yeast cells.
`The effects ofRP~l on other metalx1lic systen1s of
`C albicaru have also been investigated.-"1 For exa1nplc,
`RP~l does not inhibit anaerobic glycolysis or aerobic
`respiration, nor cloc!i it inhibit the incorporation of
`glurosaminc or N-acetyl-glucosamine. RPn·I does not
`inhibit protein synthesis in cell-free preparations of C
`a!hirans, rat liver, or mitochondria l"rom C albicmir.
`Although RPJ\·I inhibits the incorporation of glu(cid:173)
`cose into 1nannan and acetate into lipids, the synthc·
`sis of glucan is 1ninin1ally affected, indicating that
`
`45
`
`inhibition of cell \\'all synthesis is not thC [}ri111ary site(cid:173)
`of the antifungal action ot'RP1i.'.I
`TI1e 1nost profound effects of RP~[ on C alhicans
`ma)' also pmvidr clues to its actions on mainmalian
`. I
`cl'lls. For exainple, vl'r)' low conccntnitiol'ls ~.02 -
`µg/1nL) ofRPlvI inhibit the inc:orporntiori of adenine
`and phosph0.1e· into RNA and DNA. At the 1·IIC for
`RPh·I, phosphatc-roittqining ntolccuies leak out of
`the yeast cell rilcmbran~. The degradation nf these
`nuilecules, pre:Sumabl)• including nucleic acicl~, see ins
`to be pron1otrd in so1ne way hr RPJ\'1. ~1
`
`Phy~ieP·C:hemical P~opertjes of
`RPM~
`
`Structure ofRPMS
`Althougii tht: initial analrsis of the siructurc of RPM
`by infrarccl a°-d ,nuclear ~agnetic resonance (MvIR)
`spcc.troscopydid not provide tlie con1plete picture or
`its structure/; these techniques indicated that RP~,i
`was a completely nc''' type of_ macr_olide antibiotic.
`Ultimately, :-;:-ray crystallographic data clarified the
`structure ofRi>M. 71 RPn·I is__a 31 ·men1bered 1nacrqcy(cid:173)
`clc lactone coptajning-an, afnidc with a C 15 carbonyl
`and a lacton_c \\ith a C21 carqonyl (Fig 5). Additional
`analyses of th~ 110 ~nd 1H NNfR spectra of Jl.Pl\'f
`confi.r~i~cl the x·.rarcrystaJ stn1c~~1:c o~RP~I.~1 X-ray
`studies shoW~d that Rf~{ in its so_li9 crystal fonn is
`conformationally hon1ogeneous; in solution however,
`RP~! exis.ts as a mixture of two conformatinnal
`isomers caused bytraiu tocis amide isornerizatiqn vi.1.
`hindCrcd rotation about the piJlecolic add N-CO
`bond. Tile ratio.oftranr tod.r rotamcrs in chlorofonu
`solutions is 31 to 4: I ."_'1
`1
`.J.
`Illustrations of the stntc:turc ofRPl\·I wen; initially
`inconsistent; different enantiomerS were dra\\'11 15'1 a
`novel nun1bering S)'Stcnl was used,:.i :intl incorrect
`stercochcmistry at C28 was .reprc'sented."1 Ulti(cid:173)
`~ately, thcc:orrcctstructure was published,"' and the
`coordinates are deposited in the crystal data bank.
`Using advanced 2-<liinensinnal filfR spectroscopic
`ntethods, new assigmnents of the proton and carbon
`spectra fnr the ntajor rotamer of RP~{ ha\·e been
`1nade and a nc"' numbering S)'Ste1n suggested.01
`The closest stluctural relati\'c to RPJ\I is the
`antifi1ngal and i1nn1unosupprcssivc macrulidcFK.506,
`which is also produced by a strcpto1nycete.u FK.106 is
`a 23-1nen1bered macnxyde lactonc that shares a
`nniquc be1nikctal n1askcd a,f>-Oikctopipecolic add
`mnide substructure with RP~i:,'1 but lacks the Cl-C6
`triene segment nfRPn..f.
`The results of 11C-labdlcd acetate and propionate
`
`Roxane Labs., Inc.
`Exhibit 1031
`Page 008
`
`

`
`46
`
`Randall EJIU ,\loni.r
`
`and 11C-labcl!ed methionine incorporation studies of
`the bios)11thesis of RPNI were consistent with the
`proposed poly kc tide pathway in which the carbons of
`the lactonc ring ofRP~.f arc drriYc<l fron1 condensa(cid:173)
`tion of acetate and propionate units in a 1nanner
`shnilar to that responsible for fatty add synthesis.
`The methyl group of methionine is an efficient
`source for the three 1nethoxy carbons of RPWL
`Because none of the labelled precursors .was incorpo-(cid:173)
`rated into either the cyclohexane or hctcrocydic
`ring, these n1oieties probably orginate fron1
`the
`shikimatc pathway and !)'Sine, respectively.(,]
`VVhen 1H and "C Nl\·IR, infrared, lJV, mass
`spectroscopy, and optical rota1y dispersion/circular
`dichroism (ORD/CD) analyses were used to con1·
`pare the structures ofRP1''1 and 29-dctncthoA-yrnpa·
`mydn, these 1noleculeswercshown to bcconfiguration(cid:173)
`ally identical at all chiral centers and to have identical
`structural features at all but C29. Like RP1'.J, approx·
`in1ately 20% of 29-clernethoxyrapamycin in solution
`exists as thecU rota1ner IOrm.fi.l
`In addition to the naturally occurring 29·
`demethoxyraparnydn, amino acid ester analogues of
`RP1·I have been synthcsizCd to produce three water
`soluble prodrugs ofRP'l\.f4 (Fig 5). The amine fi.Inc·
`tions of the appended esters can be converted to
`water soluble salts that are enzyn1atically hydrolyzed
`in the plasma to produce RPi\L 1\lthough RP~1 forn1s
`both monocstcr and diester adducts depending on
`the reaction conditions, only monocster salts are
`
`Table 3. Physiml and Chemical Properties ofRPl\1
`
`discussed because these arc suffidently water soluble
`to ob\~ate the need for the disubstitutcd forn1s. The
`28·h)'Clroi'1.-yl group ofRP::i..f hus been proposed as the
`site of e.'licrification for each of these prodrugs, bul
`this remains to be confirnied.
`
`Physical Properties ofRP~fs
`Table 3 lists the physical properties of RPJ..t10
`W
`Although 29·dcmethoxyrapamp::in is also a white
`crystalline solid, it has a lower melting point (107" to
`JOWC) than RP~J.y, Bolh RP.~dand its 29.demethO:\.)'
`fonn are lipophilic and only n1inimally soluble in
`water. The water solubilities of both the 010110-N,N(cid:173)
`dilnethylg!ycinate methanesulfonic acid salt and thr.
`mono-N,N-dicthylpropionate hydrochloride salt pro(cid:173)
`drugs ufRPi\.I arc more than 50 n1g/mL The \~atcr
`solubility of the 111ono-+-(pyrroli<lino)butyrate hydro(cid:173)
`chloride salt prodrugis 15 n1g/mL.ri-J
`Because i\-IICs for the antifungal activity ofRP1·1
`in vitro vaiy depending on the 1nedium used and the
`length of the assay, it was suggested that RPi\'{ is
`unstable.~~ Subsequent studies showed that 5 µg/mL
`of RPt-.·I in uninoculated broth loses 80% of its
`antin1icrobial activity after 7 days of incubation at
`37"C.n Later analysis showed that 5iJ'Ai of the antimi(cid:173)
`crobial activity of 1 or 5 µg/mL concentrations of
`RP?\:f are lost after only 24- hours of incubation in
`culture mediun1.'1
`I-Iigh-prcssure liquid chromatography (I-IP

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket